Stifel lowered the firm’s price target on Nkarta (NKTX) to $11 from $12 and keeps a Buy rating on the shares. The firm believes management’s decision to forego a preliminary year-end 2025 data disclosure and instead guide to the presentation of a more-fulsome data set at a FY26 medical conference should remove a near-term overhang given the former disclosure format was perceived to be mostly inconclusive, the analyst tells investors following the Q3 update.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NKTX:
- Nkarta’s Strategic Management and Financial Strength Justify Buy Rating and $10 Target Price
- Nkarta Advances NKX019 Program Amid Financial Stability
- Nkarta reports Q3 EPS (29c), consensus (30c)
- Nkarta’s NKX019 Study: A Promising Step in Autoimmune Disease Treatment
- Nkarta, Inc. Advances CAR NK Cell Therapy Study for Immune-Mediated Diseases